The subject has a history of allergy or intolerance to flucytosine
The patient must have experienced disease progression or intolerance as outlined above after treatment with  or more prior chemotherapies
Prior therapy with PLX unless discontinued for intolerance (i.e., non-progression on prior kinase inhibitor)
Known intolerance to IMiDs.
Known intolerance to steroid therapy
Failure or intolerance to at least two prior lines of standard chemotherapies with each containing one or more of the following agents:
Participants who have demonstrated intolerance to  mg of palbociclib are ineligible for the phase I portion
Known intolerance to trastuzumab or pertuzumab or atezolizumab
Known allergy/intolerance to soy, phosphatidylcholine or any other constituents of grape seed extract
Previous known allergy or intolerance to pembrolizumab or any of its excipients
Prior ruxolitinib treatment with failure to benefit or intolerance as defined by at least one of the following:
Has been permanently discontinued from tazemetostat therapy due to adverse event, intolerance or treatment failure
Known intolerance to immunomodulatory drugs (IMiDs)
Known intolerance to the required dose and schedule of steroid therapy as determined by the investigator
Allergy or intolerance to roflumilast
History of gastritis or malabsorption syndrome or aspirin intolerance or allergy
A known allergy, intolerance, or medical contraindication to receiving the contrast dye required for the protocol-specified CT imaging
Known intolerance to steroid therapy (defined as being unable to tolerate at least  mg dex/week)
Contra indication or intolerance to required supportive care medications (aspirin and acyclovir)
Failure or intolerance to at least one prior therapy for the current disease
Known lactose intolerance.
Patients with severe intolerance to glucocorticoids
Prior treatment with (or intolerance to) at least one standard systemic regimen for the patient's respective tumor
Known allergy or intolerance to lidocaine
History of intolerance to somatostatin analogues
Intolerance to infused protein products, sucrose, histidine or polysorbate 
Patients with a history of intolerance to Das or for whom Das might not be appropriate
Patients must have refused or have evidence of intolerance to or progression on imatinib
Disease progression or intolerance to at least two prior Food and Drug Administration (FDA)-approved therapeutic regimens
Patient has a history of allergy or intolerance to flucytosine.
Progression of disease on hedgehog inhibitor (HHI) therapy or intolerance of prior HHI therapy
Patients with intolerance to compounds similar to pegylated interferon alpha-b
Patients with known allergy, intolerance, or resistance (i.e., remission duration less than  months or lack of response) to ifosfamide, carboplatin, or etoposide
A known history of intolerance to ketoconazole
A known history of intolerance to vincristine
Patient has prior history of intolerance to adjuvant interferon-alpha therapy
Hereditary fructose intolerance
History of severe allergy or intolerance to any contrast media, narcotics, sedatives, or atropine, that cannot be controlled using basic angiographic techniques
History of severe allergy or intolerance to any contrast media, narcotics, sedatives, or atropine, that cannot be controlled using basic angiographic techniques
Patients whose tumors harbor a ROS rearrangement must have demonstrated progression on or intolerance to crizotinib
Demonstrated refractoriness or intolerance to standard approved therapy (lenalidomide in del(q) MDS patients & azanucleosides in non-del(q)patients).
Intolerance of ibrutinib
Patient has a prior allergy or intolerance of ketoconazole
Patient has an allergy or intolerance to sulfites
History of allergy to or intolerance of ibrutinib or lenalidomide
Prior intolerance to a fluoropyrimidine
Intolerance of dexamethasone
Known intolerance to steroids or H/H-antagonists.
Intolerance to previous trastuzumab or pertuzumab therapy
Patients who have an allergy/intolerance to sirolimus
An adverse prognosis, documented by persistent signs and symptoms of CD that have failed to respond satisfactorily to medical and surgical therapies in the past, including but not limited to systemic immune suppressive drugs and biopharmaceuticals; to be considered as refractory to medical and surgical therapy, there must be clinical, endoscopic, and histologic evidence of active inflammatory Crohn's Disease that has either persisted or recurred despite exhaustive treatment with available pharmaceutical and surgical therapies; exhaustive treatment is defined as prior exposure to the following, without durable improvement:\r\n* Systemic glucocorticoids at or above a prednisone equivalent of  mg/day for at least  weeks, or until drug toxicity or intolerance develops\r\n* Methotrexate ( mg per week for at least  months, or until drug toxicity or intolerance develops) and/or a thiopurine antimetabolite (either . mg/kg azathioprine or . mg/kg -mercaptopurine in patients homozygous wild-type for the thiopurine-S-methyltransferase [TPMT] gene, or either . mg/kg azathioprine or  mg/kg -mercaptopurine in patients heterozygous for TPMT, or doses of these drugs capable of producing a -thioguanine nucleotide level of - without producing a -methylmercaptopurine nucleotide level above  for at least  months, or until drug allergy, intolerance or toxicity develops); if a patient is homozygous mutant for the TPMT gene, thiopurines would be contraindicated and their use would not be a requirement for enrollment in this protocol\r\n* Use of at least two anti-tumor necrosis factor (TNF)-alpha therapies, that is, infliximab (at least  mg/kg every  weeks for at least  months, or until drug allergy, toxicity or intolerance or anti-infliximab antibodies develop) and/or adalimumab (at least  mg subcutaneously [SQ] every  weeks for at least  months, or until drug allergy, toxicity or intolerance develops) and/or certolizumab pegol (at least  mg SQ every  weeks for at least  months, or until drug allergy, toxicity or intolerance develops)\r\n* Due to the serious risk of progressive multifocal leukoencephalopathy (PML) and the reluctance of some patients to agree to therapy that carries such risk, prior exposure to natalizumab is not required to meet the definition of exhaustive pharmaceutical treatment; neither will use of natalizumab among patients who are John Cunningham (JC) virus antibody seronegative be an exclusionary criterion\r\n* Exhaustive surgical treatment will be defined as indicated operations for complications of Crohn's Disease up to the point where the risks of surgery (for example, mortality or post-operative morbidity such as short bowel syndrome or extensive adhesions with high risk for inadvertent enterotomy) are deemed by patients and their physicians to be unacceptably high; indicated operations for complications of Crohn's Disease include, but are not limited to, surgical resection of involved intestine, stricturoplasty, drainage, curettage, or adhesiolysis of tissues affected by Crohn's disease\r\n* Exposure of patients to investigational drug therapies for Crohn's Disease, that is, to drugs that are not Food and Drug Administration (FDA) approved for this indication, will not be a criterion for either inclusion or exclusion
Allergy to or intolerance of prior doxorubicin-based TACE
Progression on, or intolerance of, or ineligibility for all standard therapies
Has lactose intolerance.
Intolerance to the excipients of the CTL cell product
History of severe peripheral allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically
Known intolerance to the study drug or any of the excipients.
Known intolerance to steroid therapy
History of severe allergy or intolerance to contrast agents, narcotics sedatives or atropine that cannot be managed medically
Known intolerance to lenvatinib or sorafenib (or any of the excipients)
Intolerance to dexamethasone
Known intolerance to steroid therapy
Known intolerance to steroid therapy
Has been on any number of TKIs, but has not been resistant to any TKI (changes made for intolerance are allowed)
Known intolerance to steroid therapy
Prior intolerance of irinotecan or necessity for dose reduction greater than %
F FLT CANDIDATE TRANSPLANT RECIPIENT: History of prior fluorothymidine allergy or intolerance
History of intolerance or resistance to lenalidomide
a documented NTRK fusion and a clinical history of intolerance to a prior TRK inhibitor
Known intolerance of vorinostat
Patients must have received a trial of IV cyclophosphamide pulse greater than  mg/square meter at least once within the previous  months, unless contraindicated because of severe cytopenias or intolerance
History of intolerance to irinotecan at dose-intensity of  mg/m^/ weeks or lower
History of intolerance to -FU at dose-intensity of  mg/m^/ weeks or lower
Prior intolerance to fluoropyrimidine for subjects with KRAS or NRAS mut tumor
Intolerance to dexamethasone, as determined by Investigator.
Discontinued a BTKi therapy due to BTKi treatment-related intolerance
History of severe allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically
History of prior significant toxicity or intolerance to BCG requiring discontinuation of treatment
Does the subject have a history of allergy or intolerance to flucytosine?
Prior discontinuation of cetuximab treatment due to toxicity or intolerance of cetuximab
Patients with known intolerance to low or high fat meals
History of severe intolerance to cytotoxic agent(s) given in the assigned arm
Resistance to/intolerance to hydroxyurea according to modified European Leukemia Net (ELN) criteria
allergy or intolerance to -FC
Discontinuation of previous lenalidomide or dexamethasone due to intolerance; subjects intolerant to bortezomib are not excluded
Permanent discontinuation of lapatinib in the previous study due to intolerance or treatment failure.
History of intolerance of oxycodone.
Known history of allergy or intolerance to montelukast, zafirleukast, azithromycin, erythromycin, clarithromycin, prednisone, or sirolimus
Patients with a known intolerance to lactose or other constituents of Activia
Fish and/or fish oil allergy or intolerance
Milk allergy excluding lactose intolerance
Allergy or intolerance to bupivacaine or amide anesthetics
Known allergy to or prior intolerance of aspirin and/or simvastatin
Milk protein intolerance/allergies (lactose intolerance is acceptable)
Lactose intolerance or intolerance to milk products
History of intolerance to negative pressure wound therapy
Allergy or intolerance to HT or NK- antagonists and dexamethasone
Previous intolerance/adverse effect/allergy to any component of the placebo or active agent
Known intolerance of topical steroid preparations
Patients with known fructose intolerance
Gastric intolerance attributable to ASA or NSAIDs
History of severe food intolerance to broccoli
History of allergy or intolerance to ISA
Intolerance of warm air stimulus as demonstrated by profound vertigo and nausea
Have a known allergy or food intolerance to ingredients in study products (black raspberries or other berries)
Known intolerance to NSAIDs
Intolerance to at least  prior standard therapy regimens
Gastric intolerance attributable to ASA or NSAIDs
History of prior fluorothymidine allergy or intolerance
Known intolerance to pritelivir and/or foscarnet or any of the excipients.
Known intolerance to steroid therapy
Intolerance of hyperoxia or hypercarbia as delivered by the RespirAct breathing circuit
Intolerance to broccoli/ITC-BSE taste
The patient has either failed, demonstrated intolerance, or a combination of prior failure and intolerance, to prior treatments with at least  tyrosine kinase inhibitors (TKI's). Failure of TKI treatment may either be primary (never achieved a response) or secondary resistance (loss of response).
Intolerance to TKI therapy will be defined as  of the following:
Known intolerance to study drug (or any of the excipients).